公开(公告)号：US20160158163A1

公开(公告)日：2016-06-09

申请号：US14624574

申请日：2015-02-17

Applicant: Macau University of Science and Technology

Inventor： Lai-Han LEUNG ,  Xing-Xing FAN ,  Liang LIU ,  Zebo JIANG

IPC: A61K31/09

CPC classification number: A61K31/09

Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analogue, (Z)3,4,5,4′-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analogue to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.

Abstract translation: 本发明涉及一种治疗吉非替尼耐药性非小细胞肺癌（NSCLC）的方法，包括将有效量的白藜芦醇类似物（Z）3,4,5,4'-四甲氧基二苯乙烯（TMS）给予 有需要的科目。 本发明还涉及一种诱导吉非替尼耐药NSCLC细胞凋亡的方法，包括以有效量将白藜芦醇类似物与细胞接触。 本发明的方法是通过与细胞增殖和分化相关的不同信号通路介导的，例如mTOR，JNK和某些EGFR磷酸化酪氨酸激酶。

公开(公告)号：US20150307508A1

公开(公告)日：2015-10-29

申请号：US14645406

申请日：2015-03-11

Applicant: Macau University of Science and Technology

Inventor： Lai-Han LEUNG ,  Liang LIU ,  Xing-Xing FAN ,  Jian-Lin WU

IPC: C07D491/056

CPC classification number: C07D491/056

Abstract: The present invention discloses a method of treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

Abstract translation: 本发明公开了一种治疗吉非替尼的非小细胞肺癌的方法，包括给予有效量的生物碱。 还公开了包含与用于治疗吉非替尼非小细胞肺癌的药物载体混合的生物碱的药物组合物。